New Year, New Opportunities

We've seen some incredible companies over the last few months. Our process of filtering, grilling and shepherding has always served us well and we've identified some truly brilliant teams backing exceptional products, see below for a handful of them.

iRiS – We have already secured £500,000 equity for them and as the business has such strong growth, Management have decided to extend the round for a further £3m from private investors. There’s also a very neat £2.5m loan note on offer with a 12% coupon (or 8% with conversion rights). Click here for a short video synopsis. investment round filled in record time, luckily some of our investors managed to get in on the action though many more missed out in this, their last investment round before exit in 2-3 years. Fortunately, £1.2m of shares have been made available by an existing shareholder who wishes to exit for personal reasons.

Loveholidays – This investment round filled in record time, luckily some of our investors managed to get in on the action though many more missed out in this, their last investment round before exit in 2-3 years. Fortunately, £1.2m of shares have been made available by an existing shareholder who wishes to exit for personal reasons.

Fantoo – Handpicked by Michael Dell, Fantoo are Dell’s first ever global startup-in-residence and are building a brilliant new email and messaging app for businesses (click here for the video). Their success to date has made them the poster boy for crowdcube, but have asked us to lead their next funding round, which is already half full!

Digital Assess – Although brand new to us, they’re led by a very experienced entrepreneur who has had multiple exits. The Company is a leading provider of world-class evidence based assessment for all levels of personalised learning, delivered via Software-as-a-Service. They have blue chip clients already and have a large and growing sales pipeline.

N4 Pharma – The latest offering from our Life Sciences Team, N4 Pharma are a drug reformulation company that owns and exploits powerful new techniques that improve the margins for existing drugs as well as improving productivity in drug development.